Broad-spectrum antimicrobial compositions based on combinations of taurolidine and protamine and medical devices containing such compositions
Novel antimicrobial compositions and coatings are disclosed. The antimicrobial compositions consist of mixtures of taurolidine and protamine, including protamine salts. The antimicrobial compositions are particularly useful in coatings for implantable medical devices. The antimicrobial compositions are effective against a broad spectrum of microbes.
1. An antimicrobial composition, comprising:
about 50 wt. % to about 99 wt. % of taurolidine;
about 1 wt. % to about 50 wt. % of protamine
wherein the antimicrobial composition has a Synergistic Index (SI) greater than 1.
2. The composition of claim 1 , wherein the protamine comprises a protamine salt.
3. The composition of claim 2 , wherein the protamine salt is selected from the group consisting of protamine sulfate and protamine hydrochloride.
4. The composition of claim 3 , wherein the protamine salt comprises protamine sulfate.
5. The composition of claim 1 , additionally comprising a solvent.
6. The composition of claim 5 , wherein the solvent is selected from the group consisting of water, water/ethanol, and water/isopropanol.
7. The antimicrobial composition of claim 1 , comprising:
about 70 wt. % to about 90 wt. % of taurolidine; and,
about 10 wt. % to about 30 wt. % of protamine.
8. The composition of claim 7 , wherein the protamine comprises a protamine salt.
9. The composition of claim 8 , wherein the protamine salt is selected from the group consisting of protamine sulfate and protamine hydrochloride.
10. The composition of claim 9 , wherein the protamine salt comprises protamine sulfate.
11. The antimicrobial composition of claim 1 , additionally comprising an antibiotic.
12. The antimicrobial composition of claim 11 , wherein the antibiotic is selected from the group consisting of aminoglycosides, carbapenems, cephalosporins glycopeptides, macrolides, lincosamides, penicillins, polypeptides, quinolones and tetracyclines.
13. The composition of claim 12 , wherein the antibiotic is selected from the group consisting of (gentamicin), imipenem, cefazolin, vancomycin, erythromycin, clindamycin, ampicillin, polymyxin B, levofloxacin and minocycline.
14. The antimicrobial composition of claim 1 , additionally comprising an antimicrobial agent selected from the group consisting of taurultame, cyclotaurolidine, Cilag 61 and Noxiflex S.
15. An antimicrobial coating composition for medical devices, comprising:
about 0.1 wt. % to about 10 wt. % of an antimicrobial composition, the antimicrobial composition comprising:
about 50 wt. % to about 99 wt. % of taurolidine;
about 1 wt. % to about 50 wt. % of protamine;
a solvent; and,
a polymeric binder,
wherein the antimicrobial composition has a Synergistic Index (SI) greater than 1.
16. The antimicrobial coating composition of claim 15 , wherein the solvent is selected from the group consisting of water, water/ethanol, and water/isopropanol.
17. The coating composition of claim 15 , wherein the protamine comprises a protamine salt.
18. The coating composition of claim 17 , wherein the protamine salt is selected from the group consisting of protamine sulfate and protamine hydrochloride.
19. The composition of claim 18 , wherein the protamine salt comprises protamine sulfate.
20. The antimicrobial coating composition of claim 8 , wherein the antimicrobial composition comprises:
about 70 wt. % to about 90 wt. % of taurolidine;
about 10 wt. % to about 30 wt. % of protamine; and,
a polymeric binder.
21. The coating composition of claim 20 , wherein the protamine comprises a protamine salt.
22. The coating composition of claim 21 , wherein the protamine salt is selected from the group consisting of protamine sulfate and protamine hydrochloride.
23. The coating composition of claim 22 , wherein the protamine salt comprises protamine sulfate.
24. The coating composition of claim 15 , additionally comprising an antibiotic.
25. The antimicrobial coating composition of claim 24 , wherein the antibiotic is selected from the group consisting of aminoglycosides, carbapenems, cephalosporins glycopeptides, macrolides, lincosamides, penicillins, polypeptides, quinolones and tetracyclines.
26. The coating composition of claim 15 , wherein the antibiotic is selected from the group consisting of gentamicin, imipenem, cefazolin, vancomycin, erythromycin, clindamycin, ampicillin, polymyxin B, levofloxacin and minocycline.
27. The antimicrobial coating composition of claim 15 , wherein the antimicrobial composition additionally comprises an antimicrobial agent selected from the group consisting of taurultame, cyclotaurolidine, Cilag 61 and Noxiflex S.
28. The antimicrobial coating composition of claim 15 additionally comprising a polymeric binder.
29. The antimicrobial coating composition of claim 28 , wherein the polymeric binder is selected from the group consisting of polyvinylpyrrolidones, polyethyleneglycols, carboxymethylcellulose, hydroxyethylstarch, hydroxypropyl starch, dextrane, polyoxypropylene-polyoxyethylene copolymers, polyethoxylated castor oils, polyhydroxy acids, polylactides, polyglycolides, polyhydroxy butyrates, polyhydroxy valeriates, polycaprolactones, polydioxanones, synthetic and natural oligo- and polyamino acids, polyphosphazenes, polyanhydrides, polyorthoesters, polyoxaesters, polyphosphates, polyphosphonates, polyalcohols, polysaccharides, polyethers, polyamides, aliphatic polyesters, aromatic polyesters, resorbable glasses, fibrin, collagen, albumin, polypropylene, polyethylene, partially halogenated polyolefins, wholly halogenated polyolefins, fluorinated polyolefins, polytetrafluorethylene, polyvinylidene fluoride, polyisoprenes, polystyrenes, polysilicones, polycarbonates, polyarylether ketones, polymethacrylic acid esters, polyacrylic acid esters, polyimides, cellulose, and bacterial cellulose.
30. A coated medical device, comprising:
a medical device having at least one surface; and,
an antimicrobial coating on at least a part of said surface, wherein the coating comprises
about 50 wt. % to about 99 wt. % of taurolidine; and,
about 1 wt. % to about 50 wt. % of protamine,
wherein the antimicrobial composition has a synergistic index (SI) of greater than 1.
31. The coated medical device of claim 30 , wherein the device is selected from the group consisting of surgical sutures, surgical needles, meshes, catheters, staples, tacks, stents, tapes, clips, plates, screws, suture anchors, orthopedic implants, tissue engineering substrates, tissue repair fabrics, breast implant, surgical foams, pouches, heart valves, sewing rings, pace makers, and dressings.
32. The medical device of claim 30 , wherein the device comprises a material selected from the group consisting of polymers, metals, ceramics, composites, biomaterials, and combinations thereof.
33. The medical device of claim 30 , wherein the protamine comprises a protamine salt.
34. The medical device of claim 33 , wherein the protamine salt is selected from the group consisting of protamine sulfate and protamine hydrochloride.
35. The medical device of claim 34 , wherein the protamine salt comprises protamine sulfate.
36. The coated medical device of claim 30 , wherein the antimicrobial coating comprises:
about 70 wt. % to about 90 wt. % of taurolidine; and,
about 10 wt. % to about 30 wt. % of protamine.
37. The medical device of claim 36 , wherein the protamine comprises a protamine salt.
38. The medical device of claim 37 , wherein the protamine salt is selected from the group consisting of protamine sulfate and protamine hydrochloride.
39. The medical device of claim 38 , wherein the protamine salt comprises protamine sulfate.
40. The coated medical device of claim 30 , wherein the antimicrobial coating additionally comprises an antibiotic.
41. The coated medical device of claim 40 wherein the antibiotic is selected from the group consisting of aminoglycosides, carbapenems, cephalosporins glycopeptides, macrolides, lincosamides, penicillins, polypeptides, quinolones and tetracyclines.
42. The coated medical device of claim 41 , wherein the antibiotic is selected from the group consisting of gentamicin, imipenem, cefazolin, vancomycin, erythromycin, clindamycin, ampicillin, polymyxin B, levofloxacin and minocycline.
43. The coated medical device of claim 30 , wherein the antimicrobial coating additionally comprises an antimicrobial agent selected from the group consisting of taurultame, cyclotaurolidine, Cilag 61 and Noxiflex S.
44. The coated medical device of claim 30 , wherein the antimicrobial coating additionally comprises a polymeric binder.
45. The coated medical device of claim 44 wherein the polymeric binder is selected from the group consisting of polyvinylpyrrolidones, polyethyleneglycols, carboxymethylcellulose, hydroxyethylelstarch, hydroxypropyl starch, dextrane, polyoxypropylene-polyoxyethylene copolymers, polyethoxylated castor oils, polyhydroxy acids, polylactides, polyglycolides, polyhydroxy butyrates, polyhydroxy valeriates, polycaprolactones, polydioxanones, synthetic and natural oligo- and polyamino acids, polyphosphazenes, polyanhydrides, polyorthoesters, polyoxaesters, polyphosphates, polyphosphonates, polyalcohols, polysaccharides, polyethers, polyamides, aliphatic polyesters, aromatic polyesters, resorbable glasses, fibrin, collagen, albumin, polypropylene, polyethylene, partially halogenated polyolefins, wholly halogenated polyolefins, fluorinated polyolefins, polytetrafluorethylene, polyvinylidene fluoride, polyisoprenes, polystyrenes, polysilicones, polycarbonates, polyarylether ketones, polymethacrylic acid esters, polyacrylic acid esters, polyimides, cellulose, and bacterial cellulose.
46. A method of coating a medical device, comprising the steps of: providing a medical device having at least one surface; and, coating at least a section of the surface with an antimicrobial coating composition, wherein the coating comprises: about 50 wt. % to about 99 wt. % of taurolidine; and, about 1 wt. % to about 50 wt. % of protamine, wherein the antimicrobial composition has a synergistic index (SI) of greater than 1.
47. The method of claim 46 , wherein the protamine comprises a protamine salt.
48. The method of claim 47 , wherein the protamine salt is selected from the group consisting of protamine sulfate and protamine hydrochloride.
49. The method of claim 48 , wherein the protamine salt comprises protamine sulfate.
50. The method of claim 46 , wherein the coating additionally comprises a solvent.
51. The method of claim 50 , wherein the solvent is selected from the group consisting of water, water, water/ethanol, and water/isopropanol.
52. The method of claim 46 , wherein the antimicrobial coating composition comprises:
about 70 wt. % to about 90 wt. % of taurolidine; and,
about 10 wt. % to about 30 wt. % of protamine.
53. The method of claim 52 , wherein the protamine comprises a protamine salt.
54. The method of claim 53 , wherein the protamine salt is selected from the group consisting of protamine sulfate and protamine hydrochloride.
55. The method of claim 52 , wherein the protamine salt comprises protamine sulfate.
56. The method of claim 46 , wherein the antimicrobial coating composition additionally contains an antibiotic.
57. The method of claim 56 , wherein the antibiotic is selected from the group consisting of aminoglycosides, carbapenems, cephalosporins glycopeptides, macrolides lincosamides penicillins polypeptides quinolones and tetracyclines.
58. The method of claim 57 , aminoglycosides, carbapenems, cephalosporins glycopeptides, macrolides, lincosamides, penicillins, polypeptides, quinolones and tetracyclines.
59. The method of claim 46 antimicrobial, wherein the antimicrobial coating composition additionally comprises an antimicrobial agent selected from the group consisting of taurultame, cyclotaurolidine, Cilag 61 and Noxiflex S.
60. The method of claim 46 , wherein the antimicrobial coating composition additionally comprises a polymeric binder.
61. The method of claim 60 , wherein the polymeric binder is selected from the group consisting of polyvinylpyrrolidones, polyethyleneglycols, carboxymethylcellulose, hydroxyethylelstarch, hydroxypropyl starch, dextrane, polyoxypropylene-polyoxyethylene copolymers, polyethoxylated castor oils, polyhydroxy acids, polylactides, polyglycolides, polyhydroxy butyrates, polyhydroxy valeriates, polycaprolactones, polydioxanones, synthetic and natural oligo- and polyamino acids, polyphosphazenes, polyanhydrides, polyorthoesters, polyoxaesters, polyphosphates, polyphosphonates, polyalcohols, polysaccharides, polyethers, polyamides, aliphatic polyesters, aromatic polyesters, resorbable glasses, fibrin, collagen, albumine, polypropylene, polyethylene, partially halogenated polyolefins, wholly halogenated polyolefins, fluorinated polyolefins, polytetrafluorethylene, polyvinylidene fluoride, polyisoprenes, polystyrenes, polysilicones, polycarbonates, polyarylether ketones, polymethacrylic acid esters, polyacrylic acid esters, polyimides, cellulose, and bacterial cellulose.
62. The method of claim 46 , wherein the medical device is selected from the group consisting of surgical sutures, surgical needles, meshes, catheters, staples, tacks, stents, tapes, clips, plates, screws, suture anchors, orthopedic implants, tissue engineering substrates, breast implant, surgical foams, pouches, heart valves, sewing rings, pace makers, and dressings.
63. The method of claim 46 , wherein the medical device comprises a material selected from the group consisting of polymers, metals, ceramics, composites, biomaterials, and combinations thereof.
64. A polymeric resin composition for manufacturing a medical device, comprising: a polymeric resin; and, an antimicrobial composition comprising: about 50 wt. % to about 99 wt. % of taurolidine; and, about 1 wt. % to about 50 wt. % of protamine, wherein the antimicrobial composition has a synergistic index (SI) of greater than 1.
65. The resin composition of claim 1 , wherein the protamine comprises a protamine salt.
66. The resin composition of claim 65 , wherein the protamine salt is selected from the group consisting of protamine sulfate and protamine hydrochloride.
67. The resin composition of claim 66 , wherein the protamine salt comprises protamine sulfate.
68. The medical device of claim 31 , wherein the tissue repair fabric is selected from the group consisting of meshes, woven fabrics, nonwoven fabrics and tapes.
69. The medical device of claim 32 , wherein the polymer is selected from the group consisting of polyhydroxy acids, polyalkenes, polysilicones, fluorinated polyolefins, fibrin, and collagen.
70. The medical device of claim 30 , wherein the device is implantable.
71. The method of claim 46 , wherein the device is implantable.
72. The composition of claim 1 , wherein the composition is suitable for implantation.
73. The coating composition of claim 15 , wherein the coating is suitable for application to an implantable medical device.